Black Friday is Now! Don’t miss out on up to 60% OFF InvestingProCLAIM SALE

Barclays initiates coverage of Organon with Overweight rating, projecting 70% upside

EditorAmbhini Aishwarya
Published 2023-09-22, 03:46 a/m
© Reuters.
OGN
-

On Thursday, Barclays (LON:BARC) initiated its coverage on the global healthcare company, Organon (NYSE:OGN), with an Overweight recommendation. The bank set an average one-year price target of $31.62 for the company, a potential increase of 70.18% from its last reported closing price of $18.58. The price forecasts for the healthcare firm range from a low of $23.23 to a high of $45.15.

The projected annual revenue for Organon stands at $6,376MM, indicating a growth rate of 3.37%. The company's projected non-GAAP EPS is 4.89. The company declared a regular quarterly dividend of $0.28 per share ($1.12 annualized) on August 8, 2023, which was paid out to shareholders of record as of August 18, 2023, on September 14, 2023.

Organon's current share price is $18.58 per share, yielding a dividend yield of 6.03%. Over the past five years, the average dividend yield has been 4.33%, with the lowest being 2.95% and the highest reaching up to 6.87%. The current dividend yield is significantly above the historical average by approximately 1.64 standard deviations.

Despite the attractive yield, it should be noted that nearly 38% of Organon's income is paid out in dividends as indicated by the company's dividend payout ratio of 0.38. However, Organon has not increased its dividend in the past three years.

Institutional ownership in Organon currently comprises 1274 funds or institutions, marking a decrease of about 6.19% or 84 owners in the last quarter. The total shares owned by institutions have also decreased by around 3.02% to 229,416K shares in the last three months. The put/call ratio of Organon stands at 1.12, suggesting a bearish outlook.

Among the shareholders, Mawer Investment Management holds 13,194K shares, which represents 5.16% ownership of the company. Massachusetts Financial Services owns 8,844K shares, accounting for 3.46% of the company. Invesco has 8,277K shares, representing 3.24% ownership. Vanguard Total Stock Market Index Fund Investor Shares and Vanguard Small-Cap Index Fund Investor Shares hold 7,930K and 6,585K shares, respectively.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.